ROCKET PHARMACEUTICALS, INC. (RCKT) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US77313F1066
ROCKET PHARMACEUTICALS, INC. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 0.00 USD |
| Operating income | -231.75 m USD |
| EBIT | -221.23 m USD |
| Net income | -223.12 m USD |
| Diluted EPS – continuing operations | -2.01 USD |
Full history since 2012, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About ROCKET PHARMACEUTICALS, INC.
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage. It also develops ex vivo lentiviral (LV) programs, which include programs for Leukocyte Adhesion Deficiency-I (LAD-I), a genetic disorder that causes the immune system to malfunction (RP-L201); Fanconi Anemia (FA), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells (RP-L102); and Pyruvate Kinase Deficiency (PKD), a red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia (RP-L301). It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red de Enfermedades Raras, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and Temple University. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.
More stocks
- Jiangsu Topfly New Materials (001373.SZ)
- Indexa Capital Group, S.A. (INDXA.MC)
- Letong Chemical Co Ltd (002319.SZ)
- Zoy Home Furnishing Co Ltd (603709.SS)
- Heung-A Shipping Co. Ltd. (003280.KS)
- Chunbo Co. Ltd (278280.KQ)
- Runway Growth Finance Corp. (RWAY)
- Handsome (020000.KS)
- Q32 Bio Inc. (QTTB)
- Eisen und Huettenwerke (EIS.F)
- Sarawak Plantation Bhd (5135.KL)
- Zhejiang Dilong New Material Co Ltd (002247.SZ)
Not investment advice. All data without warranty, price as of 11.11.2026. Details in the risk notice.